Erythropoietin Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Biologics & Biosimilars); By Product (Erythropoietin, Darbepoetin-alfa); By Application; By Region; Segment Forecast, 2024 - 2032
- Published Date:Jan-2024
- Pages: 116
- Format: PDF
- Report ID: PM3354
- Base Year: 2023
- Historical Data: 2019-2022
Report Outlook
The global erythropoietin drugs market was valued at USD 6.83 billion in 2023 and is expected to grow at a CAGR of 1.3% during the forecast period. The market is growing due to several factors such as the rising incidence of anemia, increasing demand for biosimilars, technological advancements, increasing prevalence of chronic kidney disease, and expanding healthcare infrastructure in emerging markets. Erythropoietin drugs are a primary treatment for anemia and biosimilars are becoming increasingly popular due to their cost-effectiveness.
To Understand More About this Research: Request a Free Sample Report
Advanced manufacturing techniques and the increasing prevalence of chronic kidney disease also contribute to the market's growth. Additionally, the expanding healthcare infrastructure in emerging markets is expected to drive the demand for erythropoietin drugs in the forecast period.
This hormone plays an important role in releasing oxygen levels in the body when they are low. However, while erythropoietin is a crucial treatment for conditions such as anemia, cancer, and HIV, it can also have adverse effects such as kidney tumors, increased blood viscosity, and bone marrow disorders. Chronic diseases often lead to anemia, and erythropoietin is commonly used to treat this condition. Patients with severe anemia who are receiving or not receiving dialysis can use epoetin to boost their red blood cell count.
Many market players in the pharmaceutical industry are investing in advanced technologies and processes to remain competitive in the erythropoietin drug market. This has led to an increased demand for cutting-edge equipment. A new and innovative production method for erythropoietin drugs was introduced in January 2021, which improves the efficiency, effectiveness, and scalability of production. The technology is based on advanced manufacturing techniques, enhancing the quality of the drug product, which is crucial in a market characterized by strong competition and evolving consumer demands. The implementation of this technology is expected to drive further growth and expansion of the market by ensuring high-quality and affordable products.
The COVID-19 pandemic has impacted the market in several ways. One of the major impacts has been the disruption of supply chains and manufacturing operations due to lockdowns and travel restrictions. Many pharmaceutical companies producing erythropoietin drugs have faced challenges in maintaining the supply of raw materials and finished products. For example, in May 2020, the European Medicines Agency (EMA) reported a shortage of Eprex (epoetin alfa), a widely used erythropoietin drug, due to manufacturing issues caused by the pandemic.
This has led to a shortage of EPO drugs in some regions, affecting patient access to treatment. In addition, the pandemic has led to a reduction in the number of patients seeking medical care, including those with chronic kidney disease and cancer. This has resulted in a decrease in demand for Erythropoietin drugs in some regions. Many healthcare facilities have also postponed non-emergency procedures, including chemotherapy for cancer patients, which has further reduced the demand.
On the other hand, some studies have suggested that COVID-19 infection can cause anemia in some patients, which may increase the demand for these drugs in those patients. Despite the challenges posed by the pandemic, many pharmaceutical companies producing erythropoietin drugs have continued to invest in research and development to improve existing formulations and develop new products. In addition, the adoption of telemedicine and home healthcare services has increased, which may help to improve patient access to these drugs in some regions.
Industry Dynamics
Growth Drivers
Increasing prevalence of cancer, particularly in developing countries, is expected to drive the growth of the market. According to the World Health Organization, there were 19.3 million new cases of cancer in 2020. Chemotherapy-induced anemia is a common complication of cancer treatment, and these drugs are often used to treat this condition. Moreover, rise in the cases of kidney related disorders likely to drive market forward. The National Kidney Foundation reports that chronic kidney disease affects around 37 million people in the United States. This figure is expected to increase due to a rise in risk factors such as obesity, high blood pressure, and diabetes.
Additionally, the development of new formulations and delivery systems for Erythropoietin drugs is expected to boost the market growth. For example, the development of long-acting Erythropoietin drugs that can be administered once a month is expected to improve patient compliance and reduce healthcare costs. Also, the use of biosimilars is becoming more widespread, Biosimilars are biological products that are highly similar to an existing biologic drug and have no clinically meaningful differences in terms of safety, efficacy, and quality. Biosimilars are becoming increasingly popular due to their lower cost compared to reference products. As a result, the use of biosimilars is becoming more widespread in the erythropoietin drugs market, which is driving down the cost of erythropoietin drugs and increasing access to treatment.
Report Segmentation
The market is primarily segmented based on type, product, application, and region.
|
By Type |
By Product |
By Application |
By Region |
|
|
|
|
To Understand the Scope of this Report: Speak to Analyst
Biologics segment is expected to witness largest growth during the forecast period
Biologics segment dominated the market, accounting for a significant share of the revenue in 2022. Biologics are complex molecules that are produced from living cells and are used to treat anemia associated with chronic kidney disease, cancer, and chemotherapy. The largest growth can be attributed to the high usage rate of biologics in the U.S. market, where biosimilars have yet to gain widespread penetration.
Biosimilars segment is anticipated to register significant growth in the coming years, driven by the expiration of major patented drugs in the U.S. market. The European and APAC markets already have higher penetration rates of biosimilars. Major erythropoietin drugs that will face patent expiration during the forecast period include Aranesp & PEG-EPO, which may lose patent rights by around May 2024, in the U.S.
Erythropoietin segment accounted for the largest market share in 2022
The erythropoietin segment holds the largest share of the market. This can be attributed to the wide usage of erythropoietin drugs in various indications, including anemia associated with chronic kidney disease, cancer chemotherapy, and HIV therapy. A study conducted by NCBI reported that Epoetin-beta was more effective in maintaining haemoglobin concentration in hemodialysis patients than Epoetin-alfa, indicating the superiority of Epoetin-beta over Epoetin-alfa in terms of therapeutic efficacy. As a result, the market for Epoetin-beta is expected to grow positively in the future.
Darbepoetin-alfa registered a significant growth rate during the forecast period. This growth can be attributed to the financial assistance provided by the company, Amgen, to the patients for buying ARANESP. In the US, Amgen's Safety Net Foundation offers financial assistance to uninsured patients, while insured patients can benefit from discount programs associated with Aranesp. This initiative by Amgen is expected to increase the adoption of darbepoetin-alfa and drive the growth of the segment in the forecast period.
Renal disease segment is expected to hold the significant revenue share over forecast period
The renal diseases segment holds the largest share in 2022. This is due to the availability of erythropoietin drugs for the treatment of various renal diseases. Some of the commonly used drugs for renal diseases include Epogen, Aranesp, Venofer, and Ferrlecit. These drugs account for about 25% of the total drug payments for anemia management in patients with chronic kidney disease, according to the Medicare and Beneficiary report. Additionally, the well-developed reimbursement policies for renal transplants and related diseases are also driving this segment.
The cancer segment is expected to witness the fastest growth in the market over the forecast period due to the increasing incidence of cancer worldwide. Factors such as the western lifestyle, smoking, and physical in-activity contribute to the disease burden. Erythropoietin drugs, have been used to increase hemoglobin levels in cancer patients with chemotherapy-associated anemia.
Other segments include the hematology segment, which is expected to grow due to the increasing prevalence of hematological disorders such as myelodysplastic syndromes and lymphomas. Additionally, the segment for surgery and trauma patients is also expected to grow as erythropoietin drugs are used to manage anemia in patients undergoing major surgeries. Overall, the increasing prevalence of anemia and related disorders and favorable reimbursement policies are expected to drive the market in the coming years.
The demand in North America is anticipated to witness significant growth
The region benefits from the presence of several organizations that are actively involved in advancing the development and use of erythropoietin drugs. In the U.S., the Medicare program covers the cost of erythropoietin drugs for patients with chronic kidney disease (CKD) or those undergoing dialysis. Additionally, the U.S. Food and Drug Administration (FDA) has approved several erythropoietin drugs for the treatment of anemia, including Epogen, Aranesp, and Procrit.
On the other hand, the Asia Pacific region is expected to witness significant growth over the forecast period. The presence of key players in the region and their strategic initiatives to develop and commercialize new erythropoietin drug products for the treatment of anemia patients is expected to drive market growth. For instance, in September 2021, Wanbang Biopharma received approval from the National Medical Products Administration (NMPA) for its Human Erythropoietin Injection, Yi Bao, which is indicated to treat chemotherapy-associated anemia in patients with non-myeloid malignancies.
Europe had significant revenue shares of the market. The region's well-established healthcare infrastructure and favorable reimbursement policies for anemia treatment are expected to fuel market growth. In addition, key regional players are actively developing and launching new erythropoietin drug products. For instance, in November 2021, Vifor Pharma received approval from the European Medicines Agency (EMA) for its new erythropoietin product, Raplixa, which is indicated for the treatment of anemia in patients with CKD.
Competitive Insight
Some of the major players operating in the global market include Amgen, Johnson & Johnson, Roche Ltd., Pfizer, Biocon, Teva Pharmaceutical, Kyowa Kirin, LG Life Sciences, AstraZeneca, Intas Pharmaceuticals, Shire, Sanofi, Novartis, Boehringer Ingelheim, and Baxter International.
Recent Developments
- In February 2023, Jesduvroq tablets from GSK received approval from the U.S. Food and Drug Administration as the initial oral therapy for treating anaemia in adults with chronic kidney disease who have been undergoing dialysis for a minimum of four months. This approval marks a significant milestone in the treatment of anaemia caused by chronic kidney disease as it provides a more convenient and accessible treatment option for patients.
- ?In November 2022, Dong-ST & Polifarma collaborated entered into agreement for its DA-3880 NESP biosimilar. This collaboration granted Polifarma the commercialization and development rights of this drug in Brazil, Mexico, & Turkey.
Erythropoietin Drugs Market Report Scope
|
Report Attributes |
Details |
|
Market size value in 2024 |
USD 6.91 billion |
|
Revenue forecast in 2032 |
USD 7.65 billion |
|
CAGR |
1.3% from 2024- 2032 |
|
Base year |
2023 |
|
Historical data |
2019- 2022 |
|
Forecast period |
2024- 2032 |
|
Quantitative units |
Revenue in USD billion and CAGR from 2024 to 2032 |
|
Segments covered |
By Type, By Product, By Application, By Region |
|
Regional scope |
North America, Europe, Asia Pacific, Latin America; Middle East & Africa |
|
Key companies |
Amgen Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., Biocon Ltd., Teva Pharmaceutical Industries Ltd., Kyowa Kirin Co. Ltd., LG Life Sciences Ltd., AstraZeneca plc, Intas Pharmaceuticals Ltd., Shire plc, Sanofi S.A., Novartis International AG, Boehringer Ingelheim International GmbH, Baxter International Inc. |
FAQ's
The erythropoietin drugs market report covering key segments are type, product, application, and region.
Erythropoietin Drugs Market Size Worth $7.65 Billion By 2032.
The global erythropoietin drugs market expected to grow at a CAGR of 1.3% during the forecast period.
North America is leading the global market.
key driving factors in erythropoietin drugs market are increasing incidence of chronic diseases.
